Medulloblastoma (MB) is the most common malignant brain tumor in children and among the subtypes, Group 3 MB has the worst outcome. Here, we perform an in vivo, patient-specific screen leading to the identification of Otx2 and c-MYC as strong Group 3 MB inducers. We validated our findings in human cerebellar organoids where Otx2/c-MYC give rise to MB-like organoids harboring a DNA methylation signature that clusters with human Group 3 tumors. Furthermore, we show that SMARCA4 is able to reduce Otx2/c-MYC tumorigenic activity in vivo and in human cerebellar organoids while SMARCA4 T910M, a mutant form found in human MB patients, inhibits the wild-type protein function. Finally, treatment with Tazemetostat, a EZH2-specific inhibitor, reduces Otx2/c-MYC tumorigenesis in ex vivo culture and human cerebellar organoids. In conclusion, human cerebellar organoids can be efficiently used to understand the role of genes found altered in cancer patients and represent a reliable tool for developing personalized therapies.

Ballabio, C., Anderle, M., Gianesello, M., Lago, C., Miele, E., Cardano, M., Aiello, G., Piazza, S., Caron, D., Gianno, F., Ciolfi, A., Pedace, L., Mastronuzzi, A., Tartaglia, M., Locatelli, F., Ferretti, E., Giangaspero, F., Tiberi, L., Modeling medulloblastoma in vivo and with human cerebellar organoids, <<NATURE COMMUNICATIONS>>, 2021; 11 (1): 1-18. [doi:10.1038/s41467-019-13989-3] [https://hdl.handle.net/10807/228208]

Modeling medulloblastoma in vivo and with human cerebellar organoids

Locatelli, Franco
Writing – Review & Editing
;
2020

Abstract

Medulloblastoma (MB) is the most common malignant brain tumor in children and among the subtypes, Group 3 MB has the worst outcome. Here, we perform an in vivo, patient-specific screen leading to the identification of Otx2 and c-MYC as strong Group 3 MB inducers. We validated our findings in human cerebellar organoids where Otx2/c-MYC give rise to MB-like organoids harboring a DNA methylation signature that clusters with human Group 3 tumors. Furthermore, we show that SMARCA4 is able to reduce Otx2/c-MYC tumorigenic activity in vivo and in human cerebellar organoids while SMARCA4 T910M, a mutant form found in human MB patients, inhibits the wild-type protein function. Finally, treatment with Tazemetostat, a EZH2-specific inhibitor, reduces Otx2/c-MYC tumorigenesis in ex vivo culture and human cerebellar organoids. In conclusion, human cerebellar organoids can be efficiently used to understand the role of genes found altered in cancer patients and represent a reliable tool for developing personalized therapies.
2020
Inglese
Ballabio, C., Anderle, M., Gianesello, M., Lago, C., Miele, E., Cardano, M., Aiello, G., Piazza, S., Caron, D., Gianno, F., Ciolfi, A., Pedace, L., Mastronuzzi, A., Tartaglia, M., Locatelli, F., Ferretti, E., Giangaspero, F., Tiberi, L., Modeling medulloblastoma in vivo and with human cerebellar organoids, <<NATURE COMMUNICATIONS>>, 2021; 11 (1): 1-18. [doi:10.1038/s41467-019-13989-3] [https://hdl.handle.net/10807/228208]
File in questo prodotto:
File Dimensione Formato  
s41467-019-09487-1.pdf

accesso aperto

Licenza: Creative commons
Dimensione 6.27 MB
Formato Adobe PDF
6.27 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/228208
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 89
  • ???jsp.display-item.citation.isi??? 81
social impact